This information has been developed and provided by Thomson CenterWatch.

Epilepsy and non-controlled partial seizures

We are conducting a clinical research study for volunteers diagnosed with Epilepsy with partial-onset seizures with or without secondarily generalization. This study tests the effectiveness of an investigational drug on total partial seizure frequency in adolescent and adult patients 12 years and older taking a maximum of three antiepileptic medications.

Study Criteria:

• Age 12-80
• Diagnosed with Epilepsy supported by a clinical history, EEG and CT/MRI within the last 10 years
• Non-controlled partial seizures despite having been treated with at least two different antiepileptic drugs for at least two years.
• Must experience at least 6 seizures during a 56-day baseline with no 21-day seizure free periods.
• Current treatment with a maximum of three approved antiepileptic drugs and on a stable dose for one month prior to screening.
• If using vagal nerve stimulator (VNS), it must have been implanted for at least six months prior to randomization
• Cannot have a diagnosis of major active psychiatric disease and/or attempted suicide within the previous 10 years
• Cannot have a progressive central nervous system (CNS) disease, including degenerative CNS disease and progressive tumors
• No history of drug and/or alcohol
• Cannot frequently need rescue benzodiazepines (more than once a month)
• No known hypersensitivity to rufinamide, triazole derivatives, or to any excipients used in the formulation

If eligible, you will receive investigational drug and study-related medical care at co cost. Travel and parking costs may also be available.

For additional information about this study or to enroll, visit our website:
www.clinicaltrialsinc.com

• Return to Study Results

This page is provided by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.